Navigation Links
Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session

PLYMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-FirstCall/ -- Genaera Corporation today announced that data from a preclinical study of trodusquemine (MSI-1436) for the treatment of obesity were presented during the American Diabetes Association (ADA) 67th Scientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz, Genaera research scientist and lead author of Abstract #1801-P, presented, "Trodusquemine is a Multiple Pathway Inhibitor that Causes Differential Weight Loss, Reduces Adiposity, and Improves Plasma Insulin and Leptin Levels."

The poster presentation summarizes results from preclinical studies demonstrating that trodusquemine suppresses appetite and causes differential weight loss in a mouse model of diet-induced obesity (DIO). Data presented also indicates that trodusquemine selectively inhibits PTP-1B, an enzyme central to controlling the function of both the leptin and insulin pathways. In addition, trodusquemine was shown to reduce the size of adipocytes, reduce body fat with no reduction of lean mass, and improve glucose tolerance via inhibition of a unique combination of signaling pathways in the DIO mouse model, making trodusquemine a promising therapeutic candidate.

"This preclinical data supports our current Phase 1 clinical strategy for trodusquemine as a treatment for obesity and further reinforces our belief that trodusquemine may also be successful in the treatment of type 2 diabetes," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We believe that, if successful, trodusquemine could be an effective monotherapy able to treat both obesity and type 2 diabetes, and could revolutionize the way these metabolic diseases are treated."

Scientists from Genaera will be available for discussion of the poster today from 12:00 p.m. to 2:00 p.m. Central Time in the Poster Hall at the conference.

For more information online, please visit: '"/>




Page: 1 2 3 4

Related medicine technology :

1. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:8/25/2008)...vention and Treatment Strategies--, PHILADELPHIA,...e,discovered gene mutations that are the main caus... neuroblastoma. In addition, the researchers found...n high-risk forms of,non-inherited neuroblastoma, ...very enables us to offer the first genetic tests t...
(Date:8/25/2008)...atient calls it a ,miracle, LATHAM, N.Y., Aug. 2...age Guided Radiation Therapy program at Community ...cancer patients using RapidArc(TM),radiotherapy te..., an,advancement that delivers a highly-precise im...) treatment in two minutes or less., RapidArc tre...
(Date:8/25/2008)... CLL Retreatment and Japanese Development Studies ...N, Denmark, August 25 /- Ge...ofatumumab in chronic lymphocytic,leukemia and non...nced today plans to begin four studies of,ofatumum...cular,non-Hodgkin,s lymphoma (NHL) this year., "G...
(Date:8/22/2008)...ust 22 /-, - Dangerous Bacteria Infe...etimes something well-tried can also be innovative... to be very antimicrobial. This,ability is now pla...gerous,hospital germs. In a worldwide noted field ...c in Wandsbek in Hamburg, Germany, was equipped wi...
Breaking Medicine Technology:Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 3Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 1Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference 714 2Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 1Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference 712 2Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 1Beaumont Patients 1st to get Next Generation of Radiation Treatment 337 2Repeat steroids to premature infants linked to cerebral palsy 1654 1Repeat steroids to premature infants linked to cerebral palsy 1654 2
...-Apr 16, 2007 - Amgen,(Nasdaq:AMGN) today presente...cebo-controlled Phase 3 study evaluating the,effic...r the,treatment of anemia in patients with active ...("the 103 study"). Aranesp is not,approved for use...ts were presented in an oral session at the 2007 A...
... approach for the treatment,of early and metastati...wswire-FirstCall/ - AEterna,Zentaris Inc. , a glob... endocrine therapy and oncology, today presented a...ormone-releasing,hormone (GHRH) antagonist JMR-132... Cancer Research (AACR) Annual Meeting being held,...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...A new dryer that is capable of eliminating parasit... from hair with a single half hour treatment is mu...ches claim researchers. The dryer capable of dryi... lower temperature than that of a regular hair dry...
...The Pakistan Medical Association (PMA) plans to mo...ast bowlers Shoaib Akhtar and Mohammed Asif.// "T...tside world and the International Cricket Council ...was not meted out to the two," PMA president Umer ...
...'Sexual Harassment' at the workplace faced by wome...days and many of them are not ready to come out op...lkata, West Bengal, with 135 in-depth interviews o...d two private hospitals over a period of 11 months...
...Russia a country known for its lax regulations reg...rowning themselves in liquor without any person// ... So it comes as little surprise when recent estima...ie annually from disorders which are linked to alc...
Other Medicine News:Health News:Lice now dried to death by novel dryer 2Health News:Doctors, Nurses Face Sexual Harassment At Work Place 2
Inquire
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)
Adhesive tape sheets for sealing multiwell plates and blocks;
Microwell Plate Accessories
Medicine Products: